S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:CELU

Celularity (CELU) Stock Price, News & Analysis

$5.23
+0.29 (+5.87%)
(As of 05:21 PM ET)
Today's Range
$4.90
$5.24
50-Day Range
$2.81
$6.96
52-Week Range
$1.59
$8.90
Volume
48,222 shs
Average Volume
275,699 shs
Market Capitalization
$101.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Celularity MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
3.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.91mentions of Celularity in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$5.35 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.87 out of 5 stars

Medical Sector

722nd out of 938 stocks

Pharmaceutical Preparations Industry

331st out of 432 stocks

CELU stock logo

About Celularity Stock (NASDAQ:CELU)

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

CELU Stock Price History

CELU Stock News Headlines

Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
CELU Apr 2024 10.000 call
CELU Mar 2024 7.500 put
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Celularity Inc. Class A
Stocks to Watch: Intuitive Machines, Celularity
Celularity Announce 1-for-10 Reverse Stock Split
Celularity to Effect 1-for-10 Reverse Stock Split
Celularity Announces 1-for-10 Reverse Stock Split
Celularity Releases CEO Letter to Shareholders
See More Headlines
Receive CELU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celularity and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/02/2024
Today
3/28/2024
Next Earnings (Estimated)
4/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CELU
Fax
N/A
Employees
225
Year Founded
N/A

Profitability

Net Income
$14.19 million
Net Margins
-1,226.72%
Pretax Margin
-1,226.64%

Debt

Sales & Book Value

Annual Sales
$17.98 million
Cash Flow
$1.82 per share
Book Value
$13.36 per share

Miscellaneous

Free Float
15,367,000
Market Cap
$96.90 million
Optionable
Optionable
Beta
0.24
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Robert Joseph Hariri M.D. (Age 65)
    Ph.D., Founder, CEO & Chairman
    Comp: $1.24M
  • Mr. David C. Beers C.F.A. (Age 54)
    Chief Financial Officer
    Comp: $455.02k
  • Mr. John R. Haines (Age 66)
    Senior EVP, Global Manager & Chief Administrative Officer
    Comp: $503.56k
  • Ramji Krishnan
    Chief Technology Officer
  • Carlos Ramirez
    SVP of Investor Relations
  • Mr. Kyle Harold Fletcher Esq. (Age 39)
    Executive VP, General Counsel & Chief Compliance Officer
  • Dr. Stephen A. Brigido D.P.M. (Age 48)
    President of Degenerative Diseases
  • Dr. Adrian Kilcoyne M.B.A. (Age 53)
    M.D., M.P.H., Executive VP, Chief Medical Officer and Head of Global Affairs, Patient Safety & Patient Affairs
  • Sharmila Koppisetti M.D.
    Senior Vice President of Clinical Dev. Immunology & Drug Safety
  • Mr. Tim Wilk
    Senior Vice President of Technical Operations

CELU Stock Analysis - Frequently Asked Questions

How have CELU shares performed in 2024?

Celularity's stock was trading at $2.4740 at the beginning of 2024. Since then, CELU stock has increased by 111.4% and is now trading at $5.23.
View the best growth stocks for 2024 here
.

Are investors shorting Celularity?

Celularity saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 388,300 shares, a decline of 16.8% from the February 29th total of 466,600 shares. Based on an average trading volume of 269,900 shares, the short-interest ratio is presently 1.4 days. Approximately 3.7% of the shares of the company are sold short.
View Celularity's Short Interest
.

When is Celularity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024.
View our CELU earnings forecast
.

How were Celularity's earnings last quarter?

Celularity Inc. (NASDAQ:CELU) issued its quarterly earnings results on Tuesday, January, 2nd. The company reported ($0.60) earnings per share for the quarter. The company earned $3.79 million during the quarter. Celularity had a positive trailing twelve-month return on equity of 30.79% and a negative net margin of 1,226.72%.

When did Celularity's stock split?

Celularity shares reverse split on the morning of Thursday, February 29th 2024. The 1-10 reverse split was announced on Thursday, February 29th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Celularity's major shareholders?

Celularity's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (19.26%) and Vanguard Group Inc. (1.93%). Insiders that own company stock include Kok Thay Lim and Robert J Hariri.
View institutional ownership trends
.

How do I buy shares of Celularity?

Shares of CELU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CELU) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners